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A HUNGER HORMONE THAT ATTENUATES CONDITIONED FEAR?: 
INVESTIGATING THE ROLE OF GHRELIN RECEPTOR SIGNALING IN THE 
ACQUISITION AND CONSOLIDATION OF FEAR MEMORY  
SAMIKSHA SHAH 
ABSTRACT 
 Ghrelin has been established as a hunger hormone because of its role in weight 
regulation and appetite stimulation. However, recent studies have uncovered a role for 
ghrelin in the modulation of negative emotional states like fear, anxiety and depression. 
The unusually high constitutive activity of the ghrelin receptor, growth hormone 
secretagogue receptor type 1a (GHSR1a) and its extensive ability to dimerize with other 
neuromodulatory receptors highlights the complexity of ghrelin receptor signaling. This 
led us to examine one of the essential constituents of this signaling mechanism. We 
exogenously administered GHSR1a into the basolateral complex of the amygdala (BLA), 
a region known to regulate negative emotional states. The Pavlovian fear conditioning 
paradigm was used to observe and compare the fear response of rats injected with 
GHSR1a and GFP to the fear response in rats injected with GFP alone. Our analyses 
revealed a significant attenuation of aversive memory recall in rats injected with GHSR1a 
and GFP, which suggests that increased ghrelin receptor signaling due to an 
overexpression of GHSR1a in the BLA impairs the consolidation and retrieval of 
conditioned fear memory. While other constituents of the ghrelin signaling mechanism 
remain to be investigated, our study provides an initial step in establishing ghrelin as a 
novel biomarker for stress-induced fear disorders. 
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INTRODUCTION 
 
 In 1999, Kojima and his colleagues reported the purification and identification of 
an endogenous ligand in the rat stomach, using a stable cell line expressing the orphan G-
protein coupled growth hormone secretagogue receptor (GHS-R) (Kojima et al., 1999). 
The purified ligand, a 28 amino acid peptide, is activated by post-translational acylation 
to release growth hormone (GH) in vitro and in vivo (Kojima et al., 1999; Meyer, Burgos-
Robles, Liu, Correia, & Goosens, 2014). This GH-releasing peptide was called “ghrelin”, 
from the Indo-European word “ghre” which means “to grow”(Kojima et al., 1999).  
 
Ghrelin: Not just a hunger hormone? 
In the years that followed its discovery, ghrelin came to be known as the “hunger 
hormone” (Pradhan, Samson, & Sun, 2013) because of its role in the regulation of 
nutrient sensing, meal initiation, and its stimulatory effect on appetite (Kirchner, 
Heppner, & Tschöp, 2012; Pradhan et al., 2013; Sato et al., 2012). Research in the past 
decade has extended the role of ghrelin beyond its orexigenic effect to an essential 
regulatory hormone in several organ systems (Pradhan et al., 2013). Ghrelin’s reciprocal 
relationship with insulin pointed toward an important role in glucose homeostasis (Sun, 
Asnicar, & Smith, 2007) . Following this discovery, several studies began to focus on 
ghrelin as a potential therapeutic target for diabetes, obesity, and related disorders 
(Chacko et al., 2012; Li et al., 2012; Ma et al., 2012; Sun et al., 2007). More recently, a 
study demonstrated the anti-atrophic effects of both acylated and unacylated forms of 
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ghrelin on skeletal muscle (Porporato et al., 2013). Three different groups have 
highlighted the importance of ghrelin in regulating cardiac function following acute 
myocardial infarction (Cao et al., 2013; Mao et al., 2012, 2013; Yuan et al., 2012). 
Ghrelin prevented sympathetic activation and promoted myocardial angiogenesis in 
mouse and rat models of myocardial infarction, in addition to reducing inflammatory 
cytokines, apoptosis, and oxidative stress after cardiopulmonary bypass (Cao et al., 2013; 
Mao et al., 2012, 2013; Yuan et al., 2012).  
The ghrelin system has thus been shown to be involved in a diverse array of 
functions; however, studies conducted by several groups have uncovered yet another role 
for ghrelin—modulation of negative emotional states like fear, stress, anxiety, and 
depression (Jensen et al., 2016; Lutter et al., 2008a; Meyer et al., 2014). Ghrelin travels 
through the blood stream in its acylated state (Kojima et al., 1999; Meyer et al., 2014). It 
crosses the blood-brain barrier and binds to its receptor, growth hormone secretagogue 
receptor (GHSR1a), found in numerous brain regions, including the hypothalamus, 
hippocampus, brainstem, ventral tegmental area (VTA), and the amygdala (BLA)(Jensen 
et al., 2016; Meyer et al., 2014; Wellman & Abizaid, 2015). Within the amygdala, the 
basolateral (BLA) has been identified as the sub-region with the highest concentration of 
ghrelin receptors (Alvarez-Crespo et al., 2012; Meyer et al., 2014). Incidentally, the 
basolateral complex is known to regulate negative emotional states (Alvarez-Crespo et 
al., 2012; Currie, Schuette, Wauson, Voss, & Angeles, 2013; Jensen et al., 2016; Lutter et 
al., 2008a; Meyer et al., 2014). Exogenous administration of ghrelin in rodents has been 
shown to cause anxiolytic effects (Jensen et al., 2016; Yamamoto et al., 2009; Lutter et 
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al., 2008). These findings have been supported by studies in which ghrelin knock-out 
mice showed an anxiogenic response to acute stress (Spencer et al., 2012); however, 
various groups have published contradictory results, describing how rodents injected with 
ghrelin in the hippocampus, dorsal raphe nucleus (DRN), amygdala, and hypothalamus 
showed anxiogenic behavior (Carlini et al., 2002, 2004; Currie et al., 2012a; Spencer et 
al., 2012). A more recent study suggests that while chronic stimulation of the ghrelin 
receptor in the BLA enhances long-term fear memory, acute stimulation of the receptor 
impairs long-term fear memory (Meyer et al., 2014). These findings suggest that ghrelin 
is a critical component of the stress regulation system. Thus, determining a mechanism 
by which ghrelin potentiates or impairs aversive processing is important. 
 
An established modulator of the stress response: The Hypothalamic-pituitary-adrenal 
(HPA) axis 
Hypothalamic-pituitary-adrenal (HPA) axis hormones have been established as 
key regulators of the stress response (Aguilera, 2011; Glover, O’Connor, & O’Donnell, 
2010; Mitrovic, 2003; Pariante & Lightman, 2008; Wasserman, Wasserman, & 
Sokolowski, 2010; Wolf, 2003). The neuroendocrine response to stress is coordinated by 
corticotrophin releasing hormone (CRH) and vasopressin (VP), two hypothalamic 
peptides released by parvocellular neurons in the paraventricular nucleus (PVN) 
(Aguilera, 2011). These peptides stimulate the release of adrenocorticotropic hormone 
(ACTH) from the pituitary, which in turn stimulates glucocorticoid secretion from the 
adrenal cortex. Glucocorticoids, by crossing the blood-brain barrier, may then bind to 
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specific receptors in the brain to initiate neuromodulatory changes essential for stress 
adaption (Aguilera, 2011).  
While acute exposure to the hormones of the HPA axis is imperative for stress 
adaptation, chronic activation of the axis results in increased levels of CRH, subsequently 
increasing the vulnerability toward psychiatric, immune and metabolic disorders 
(Aguilera, 2011; McEwen, 2007; Munck & Náray-Fejes-Tóth, 1994). 
In addition to activating the HPA axis, CRH and VP neurons in several brain 
regions modulate behavioral responses (Aguilera, 2011). The CRH network has an array 
of physiological functions that constitute the stress response (Beurel & Nemeroff, 2014). 
While it stimulates catecholamine synthesis in the adrenal gland locally, it also acts as a 
modulatory factor in limbic areas, altering levels of fear, alertness, appetite and libido. 
Interestingly, several modulatory functions of CRH occur independent of HPA axis 
activation (Beurel & Nemeroff, 2014; Butler, Weiss, Stout, & Nemeroff, 1990).  
Central administration of CRH via an intracerebroventricular (ICV) route 
produced anxiety-like behavior in rats, as observed in the elevated plus maze, leaving the 
peripheral system unperturbed. (Beurel & Nemeroff, 2014; Butler et al., 1990; Sutton, 
Koob, Le Moal, Rivier, & Vale, 1982). Direct, exogenous administration of CRH into the 
central nervous system (CNS) also produced behavior that resembled enhanced fear in a 
novel open field, an acoustic startle test, and a social interaction test  (Britton, Morgan, 
Rivier, Vale, & Koob, 1985; Liang et al., 1992; Snyder, Wang, Han, McFadden, & 
Valentino, 2012). Extrahypophyseal CRH has also been shown to elicit enhanced 
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conditioned fear in rodent models following a direct infusion into the locus coeruleus of 
the brainstem (Beurel & Nemeroff, 2014; Cole & Koob, 1988; Snyder et al., 2012).  
Although several effects of chronic stress can be simulated by the exogenous 
administration of CRH in rodents, there has been insufficient evidence of the clinical 
application of these data in stress-related mental disorders (Meyer et al., 2014). In a study 
conducted by Banki et al. (1983), cerebrospinal fluid (CSF) concentration of CRH in 257 
female psychiatric patients was measured using radioimmunoassays. Patients suffering 
from schizophrenia, manic and anxiety disorders, and dementia were compared to 
neurological controls. No significant correlation was established between a single clinical 
or psychological factor and CSF concentrations of CRH (Banki, Karmacsi, Bissette, & 
Nemeroff, 1992; Binder & Nemeroff, 2010). Another study measured CSF 
concentrations of CRH in patients with panic disorder (PD), obsessive compulsive 
disorder (OCD), and generalized anxiety disorder (GAD) and found no significant 
difference in CRH levels of normal control subjects and patients with anxiety disorders 
(Fossey et al., 1996; Jolkkonen, Lepola, Bissette, Nemeroff, & Riekkinen, 1993).  
In addition to the CRH system, VP has been shown to be anxiogenic using a 
variety of experimental techniques (Beurel & Nemeroff, 2014; Neumann & Landgraf, 
2012). Intranasal injections of arginine vasopressin (AVP) bring about fluctuations in 
neural activity in the prefrontal cortex and amygdalar regions of the brain, which have 
been associated with social behavior, anxiety and fear processing (Beurel & Nemeroff, 
2014; Zink, Stein, Kempf, Hakimi, & Meyer-Lindenberg, 2010). These modulatory 
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effects of VP are mediated by V1a, V1b, and V2 receptors (Beurel & Nemeroff, 2014; 
Koshimizu et al., 2012).  
The extensive literature implicating VP in the mediation of social behavior, 
depression and anxiety disorders led to the investigation of the VP receptors as 
therapeutic targets. While some studies have shown anxiolytic effects in wild-type mice 
injected with the V1a receptor (Bielsky, Hu, Ren, Terwilliger, & Young, 2005), other 
studies (Wersinger et al., 2007) have reported normal levels of social aggression, anxiety-
like behavior, and social recognition in V1a knock-out mice as compared to wild-type 
mice. Several groups using V1b knock-out models of anxiety have reported conflicting 
observations in anxiety-like behavior (Mlynarik, Zelena, Bagdy, Makara, & Jezova, 
2007; Roper, O’Carroll, Young, Lolait, & Lolait, 2011; Wersinger, Ginns, O’Carroll, 
Lolait, & Young III, 2002), leading  Roper et al. to suggest that V1b knock-out mice are 
unsuitable models to study stress-induced anxiety disorders.  
Antagonists of the V1a and V1b receptors have been shown to reduce anxiety-like 
behavior in rodent models of anxiety, including the elevated plus maze, the conditioned 
lick suppression test, and the elevated zero maze (Bleickardt et al., 2009; Griebel et al., 
2002; Hodgson et al., 2007). However, clinical trials of a V1b antagonist, SSR149415, 
were terminated even though it showed promise as an anxiolytic agent in several rodent 
models of psychiatric disorders, (Griebel et al., 2002; Hodgson et al., 2007; Kirchhoff, 
Nguyen, Soczynska, Woldeyohannes, & McIntyre, 2009; Koshimizu et al., 2012; Roper, 
O’Carroll, Young & Lolait, 2011) emphasizing the need to advance additional V1b 
antagonists from early translational research into phase I clinical trials.  
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The AVP system acts as the primary regulator of ACTH and glucocorticoid 
release (Koshimizu et al., 2012). However, the reduction in ACTH levels brought about 
by antagonizing V1b receptors does not lead to a consequent decrease in glucocorticoid 
hormones as expected, suggesting the presence of a compensatory mechanism or 
hormone that is activated by the decrease in ACTH levels, or one that acts in conjunction 
with ACTH to stimulate glucocorticoid release (Koshimizu et al., 2012). Once 
glucocorticoid hormones are released from the adrenal cortex, they bind to 
melanocorticoid receptors (MRs) and glucocorticoid receptors (GRs) in the brain (de 
Quervain, Schwabe, & Roozendaal, 2016). While GRs are found in several regions of the 
brain, MRs are concentrated in the hippocampus and the amygdala, mediating the 
response to stressful stimuli (de Quervain et al., 2016). Lower concentrations of 
endogenous corticosteroids have been associated with acute freezing behavior as well as 
acute anxiety-like behavior in an elevated plus maze that is mediated via MRs; while 
higher concentrations strengthen the acquisition and consolidation of stressful 
experiences via GRs (Korte, 2001). However, a recent article reviewing pharmacological 
targets for the prevention of post-traumatic stress disorder (PTSD) has described how 
patients have responded well (i.e., impaired acquisition and consolidation of aversive 
stimuli) to an exogenous administration of glucocorticoids (Meyer et al., 2014; Searcy, 
Bobadilla, Gordon, Jacques, & Elliott, 2012b). Thus, both enhanced and impaired 
processing of stressful experiences have been reported as a consequence of an increased 
concentration of corticosteroids, which indicates the need for further mechanistic studies 
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to determine whether glucocorticoids act in parallel with another modulatory system that 
is simultaneously activated in response to stressful stimuli. 
In addition to regulating stress, HPA hormones are also implicated in the 
regulation of fear.  A study investigating the effect of acute corticosterone treatment on 
dendritic hypertrophy in the BLA described how a single acute dose of the hormone 
induced increased anxiety and dendritic hypertrophy in the BLA, but neither acute nor 
chronic treatment affected consolidation or retrieval of fear memory (Mitra & Sapolsky, 
2008). Another study showed that chronic corticosterone treatment only enhanced 
freezing to the context in which subjects were conditioned, not freezing to the tone 
(Conrad et al., 2004).  
There have been few successful clinical trials elucidating the role of HPA axis- 
hyperactivity in regulating fear and anxiety (Meyer et al., 2014; Searcy, Bobadilla, 
Gordon, Jacques, & Elliott, 2012). In patients with post-traumatic stress disorder (PTSD), 
exogenous administration of cortisol as a preventative agent causes a negligible change in 
hormonal levels, and fails to bring about hormonal homeostasis (Cohen et al., 2006; 
Searcy, Bobadilla, Gordon, Jacques, & Elliott, 2012). Elevated levels of cortisol have 
been linked to decreased hippocampal volume in humans; however, a correlation between 
reduced hippocampal volume and exposure to a traumatic event has not been reported 
consistently in the literature (Knoops, Gerritsen, van der Graaf, Mali, & Geerlings, 2010; 
Neylan et al., 2003; Searcy et al., 2012). Also, it is not known whether this reduced 
hippocampal volume in patients with PTSD is due to excess cortisol, or a pre-existing 
structural anomaly (Searcy et al., 2012; O’Hara et al., 2007). Both, hypo- and 
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hyperactivity of HPA hormones has been reported in humans with stress-induced mental 
illness, with some patients showing an improvement in response to stressful stimuli after 
administration of excess glucocorticoids (Meyer et al., 2014). Due to these 
inconsistencies, exploring novel biomarkers and signaling pathways that could be 
necessary, and even sufficient to mediate a response to stressful or traumatic events is 
essential. 
 
A novel biomarker for stress-related disorders: Ghrelin 
Ghrelin signaling has quickly become an important consideration in stress-related 
disorders. Increased levels of plasma ghrelin as well as gastric ghrelin mRNA have been 
reported by several studies using different rodent models of acute stress (Asakawa et al., 
2001a; Chuang & Zigman, 2010a; Jensen et al., 2016; Kristenssson et al., 2006; Lutter et 
al., 2008a). Human subjects exposed to acute psychosocial stress have also shown 
significantly elevated plasma ghrelin levels (Chuang & Zigman, 2010b; Rouach et al., 
2007). The increased levels of ghrelin in mouse models of calorie restriction have been 
associated with antidepressant effects (Chuang & Zigman, 2010b; Lutter et al., 2008a). 
These antidepressant effects are not observed in GHSR knock-out models of similar 
calorie restriction, leading several groups to hypothesize that ghrelin signaling might 
function as a compensatory mechanism that helps cope with acute and chronic exposure 
to stress (Chuang & Zigman, 2010b; Jensen et al., 2016; Lutter et al., 2008a). 
In support of literature that suggests a role for ghrelin signaling in modulating the 
stress response, epinephrine, a hormone part of the sympathetic response to stress has 
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been found to be a strong stimulator of ghrelin release (Chuang & Zigman, 2010b; Jensen 
et al., 2016). Furthermore, ghrelin -producing cells have been found in abundance in b1- 
adrenergic receptors, (Chuang & Zigman, 2010a; Jensen et al., 2016; Zhao et al., 2010) 
suggesting a potential mechanism by which increased secretion of ghrelin could exert 
negative feedback to the stress response (Jensen et al., 2016). 
There have been a number of studies that have extended the role of ghrelin to a 
key regulator of stress-induced mental illnesses in addition to its role in mediating the 
stress response (Asakawa et al., 2001b; Carlini et al., 2002; Chuang & Zigman, 2010b; 
Jensen et al., 2016; Lutter et al., 2008b; Rouach et al., 2007). One study used a food 
deprivation model to study the effect of ghrelin signaling on the strengthening of 
synapses in the lateral amygdala, an important step in the acquisition and consolidation of 
contextual and auditory fear memory (Schafe, Doyère, & Ledoux, n.d.). Food deprivation 
leads to elevated levels of plasma ghrelin (Asakawa et al., 2001b; Rouach et al., 2007). 
The increased plasma ghrelin led to an impairment in the processing of fear memory as 
observed from behavioral tests; additionally, the observed fear extinction was reversed 
when an antagonist of the ghrelin receptor type 1a, D-Lys3 growth hormone releasing 
peptide-6 (GHRP-6) was administered  (Huang, Chou, Yeh, & Hsu, 2016). 
It has been established that the ghrelin receptor GHSR1a is present in the BLA; 
however, the downstream effector of this receptor, growth hormone (GH) is also 
localized in this region (Kojima et al., 1999; Pacold, Kirsteins, Hojvat, & Lawrence, 
1978). Following a period of stress, GH levels significantly increased in the amygdala 
(Donahue, Kosik, & Shors, 2006; Meyer et al., 2014) Importantly, overexpression of GH 
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in the BLA resulted in enhanced long term fear memory, similar to enhanced fear 
learning seen in response to repeated ghrelin receptor stimulation by a ghrelin agonist in 
the BLA (Meyer et al., 2014). To determine whether the fear enhancing effect of the 
ghrelin agonist was dependent on the activity of GH in the BLA, Meyer et al. infused 
virus expressing a GH-antagonist into the BLA. This blocked the fear enhancing effect of 
repeated ghrelin receptor stimulation, uncovering the importance of a novel “ghrelin-
growth hormone axis” in the modulation of negative emotional states (Meyer et al., 
2014).  
In order to develop a model that elucidates the pathway and mechanism of action 
of ghrelin, the possibility of the ghrelin system acting in parallel with the HPA axis has 
been investigated (Asakawa et al., 2001b). One study found an interesting correlation 
between the administration of ghrelin and stimulation of CRH neurons. The authors have 
reported how the administration of ghrelin into the paraventricular nucleus stimulates 
gene expression of CRH, thereby activating the HPA axis (Cabral, Suescun, Zigman, & 
Perello, 2012). Although the immunohistochemical analysis failed to show ghrelin 
binding sites in the CRH neurons, the findings of this study point in the direction an 
indirect mechanism of action of ghrelin on CRH expression. Another study specifically 
investigated the effect of central administration of ghrelin on ACTH levels (Stevanović, 
Milošević, Starčević, & Severs, 2007). Absolute and relative weights of the pituitary 
gland, volume of ACTH cells, and the level of circulating ACTH all increased 
significantly following the injection of ghrelin into the lateral ventricle of rats, providing 
further insight into the pathway of action of ghrelin. Intraperitoneal infusions of ghrelin 
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have resulted in a dose-dependent increase of corticosterone (Asakawa et al., 2001b; 
Rouach et al., 2007) in rodents, and systemic injections of ghrelin in healthy subjects 
have led to an increase in ACTH and cortisol levels (Otto, Tschöp, Heldwein, Pfeiffer, & 
Diederich, 2004). In patients with Cushing’s syndrome, ghrelin administration triggers 
hypersecretion of ACTH and cortisol (Leal-Cerro et al., 2002). Otto et al. studied the 
effect of hypersecretion of glucocorticoids on ghrelin levels, and found that increased 
endogenous or exogenous cortisol levels caused a decrease in plasma ghrelin in humans, 
suggesting the presence of a feedback loop between the HPA axis and ghrelin secretion. 
These findings have been supported by studies in which significantly elevated levels of 
ghrelin were observed in rodents that were hypophysectomized as compared to rats that 
underwent a sham hypophysectomy or controls (Arafat et al., 2005), providing further 
evidence of a feedback mechanism between the HPA and ghrelin systems.  
Studies investigating the role of ghrelin and HPA hormones in fear learning have 
reported the projection of corticotrophin releasing factor (CRF) neurons from the 
hypothalamus to the amygdala, which suggests that ghrelin receptor agonism can be 
triggered by CRF in the amygdala (Isogawa, Bush, & LeDoux, 2013; Meyer et al., 2014; 
Roozendaal, Schelling, & McGaugh, 2008). Hypothalamic CRF is secreted by neurons in 
the paraventricular nucleus, which incidentally is an area characterized by a high density 
of the ghrelin receptor GHSR1a (Guan et al., 1997). The ghrelin system can therefore 
interact with the HPA axis hormones to coordinate modulation of fear learning.  
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Ligand-independent signaling: Constitutive activity of GHSR1a 
Until recently, a majority of studies have used acute exogenous injections of 
ghrelin or ghrelin agonists and ghrelin receptor knock out models to study anxiety-like 
behavior in rodents (Albarran-Zeckler, Sun, & Smith, 2011; Asakawa et al., 2001a; 
Lutter et al., 2008a; Meyer et al., 2014). A more recent study used a unique approach to 
study the effect of ghrelin signaling on stress and anxiety levels (Jensen et al., 2016). 
Ghrelin receptor (GHSR1a) was overexpressed in the basolateral division of the 
amygdala, while the endogenous level of ghrelin remained unaltered (Jensen et al., 2016). 
This allowed dissociation of the effect of constitutive activity of GHSR1a from the effect 
of exogenous administration of ghrelin on anxiety-like behavior.  
A significant percentage of G-protein coupled receptors (GPCRs) exhibit intrinsic 
constitutive activity; however, GHSR1a shows an unusually high constitutive activity, 
signaling at 50% of its maximum capacity in the absence of ghrelin (Arvanitakis, Geras-
Raaka, & Gershengorn, 1998; Holst, Cygankiewicz, Jensen, Ankersen, & Schwartz, 
2003; Mear, Enjalbert, & Thirion, 2013; Smit et al., 2007; Yin, Li, & Zhang, 2014). In 
addition to the physiological importance of this constitutive activity in regulation of food 
intake and weight regulation, its relevance in learning and memory has also been 
explored. For example, GHSR1a knock out mice exhibit increased spatial learning in 
behavioral tests like the Morris Water Maze, and deficits in contextual fear memory when 
exposed to a conditioned fear paradigm (Albarran-Zeckler, Brantley, & Smith, 2012; 
Mear et al., 2013). The effect of a similar acute exogenous administration of GHSR1a 
into the BLA of rodents; using a conditional fear paradigm to look at specific effects of 
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GHSR1a overexpression on fear memory consolidation and retrieval has not been 
investigated so far. 
Ligand-independent signaling of GHSR1a can also cause alteration in signaling 
cascades of systems other than ghrelin (Wellman & Abizaid, 2015). This modulation 
occurs via receptor oligomerization, wherein G-protein coupled receptors in close 
proximity of one another form dimers, resulting in physical conformations and 
subsequent changes in signaling. Signaling of the protomers part of a specific dimer pair 
can be modulated by facilitation or inhibition of the pathways as a result of the 
dimerization; and this modulation is not observed in the absence of either one of the 
protomers involved in the formation of the dimer (Wellman & Abizaid, 2015). 
The ligand-independent, constitutive signaling of GHSR1a is not imperative for 
the process of dimerization; nor is it a result of dimerization of GHSR1a (Wellman & 
Abizaid, 2015). Mutations that have induced a lower level of constitutive activity of 
GHSR1a did not interfere in the ability to form homodimers, suggesting that residues 
contributing to constitutive activity are not part of the dimerization interface (Wellman & 
Abizaid, 2015). These findings usher in the potential for several mechanistic studies to be 
conducted, specifically to determine how the ghrelin system works to regulate stress and 
stress-induced mental disorders; whether it is via ligand-independent constitutive 
signaling alone, or via a complex signaling network formed as a result of dimerization of 
GHSR1a with a variety of receptors, or a combination of the two. 
GHSR1a has the ability to dimerize with a host of receptors, including the dopamine 1 
receptor (D1R), dopamine 2 receptor (D2R), melanocortin 3 receptor (MC3R), serotonin 
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2C receptor (5-HT2C), and possibly the cannabinoid type 1 receptor (CB1) (Table 1). This 
has extensive implications in expanding pharmacological treatment of mental disorders 
characterized by feelings of fear and anxiety, as well as disorders like Parkinson’s, 
schizophrenia, addiction, and obesity (Wellman & Abizaid, 2015).  
In addition to the extensive potential pharmacological implications, evidence of 
dimerization of the GHSR1a receptor paves the way for future studies investigating the 
mechanism by which the network formed with dopamine, serotonin, melanocortin, and 
cannabinoid receptors as a result of dimerization modulates stress, as well as stress-
related mental illnesses. For instance, studies investigating the concentration of these 
dimers in different regions of the brain can form hypotheses about whether they function 
as constituents of the neural circuitry underlying several stress-induced neurological 
disorders.  
 
GHSR1a and the Dopamine system: GHSR1a-D1R and GHSR1a-D2R heterodimers 
D1 Receptors  
Expression of both, GHS-1a and D1 receptors in the cortex, substantia nigra, 
ventral tegmental area, midbrain, and amygdala, and hippocampus prompted several 
research groups to investigate the degree of co-localization at the level of single cells and 
the possibility of dimerization between these two receptors (Wellman & Abizaid, 2015). 
Jiang et al. generated a colony of Ghsr-IRES-tauGFP mice and first examined brain 
sections to determine the extent of GHSR expression. They found Ghsr-positive neurons 
in the CA1, CA2, CA3, and dentate gyrus regions of the hippocampus, the substantia 
		
16 	
nigra, the ventral tegmental area, arcuate nucleus, medial septal nucleus, lateral 
entorhinal cortex, auditory/somatosensory cortex, olfactory tubercle, medial preoptic 
area, and the amygdala. Next, they performed immunohistochemistry to detect the 
presence of D1 receptors in the brain sections with Ghsr/GFP positive neurons. GHSR1a 
and D1Rs were co-localized in the hippocampus, ventral tegmental area, substantia nigra, 
and the midbrain (Jiang et al., 2006).  
The study also demonstrated dimerization of GHSR1a with D1R receptors in 
HEK293 cells co-transfected with D1R-RLuc and GHSR-GFP plasmids by using a 
resonance energy transfer (RET) assay and co-immunoprecipitation as detectors of 
oligomerization (Jiang et al., 2006). Co-treatment of HEK293 cells with D1R and 
GHSR1a led to a four-fold increase in dopamine signaling compared to cells treated with 
D1R, as measured by cAMP accumulation (Wellman & Abizaid, 2015). This hyper-
stimulation of dopamine signaling only occurred in the presence of both the receptors and 
their respective ligands (Jiang, Betancourt, & Smith, 2006). Although the dimerization 
between GHSR1a and D1R has only been demonstrated in model systems, it provides an 
understanding of the role of ghrelin signaling in regulating reward behavior as well as 
mood disorders (Jiang et al., 2006; Zarouna, Wozniak, & Papachristou, 2015).  
Evidence of dimerization and co-localization of GHSR1a and D1Rs was provided 
in two separate experiments. Although co-localization suggests the occurrence of 
dimerization, further studies would be required to determine and confirm the degree of 
correlation between co-localization and dimerization. For instance, Kern et al. have 
demonstrated GHSR1a-D2R dimerization specifically in membrane preparations of 
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hypothalamic and striatal tissue. Similar experiments conducted in membrane 
preparations of hippocampal or ventral tegmental tissue (established as areas of co-
localization of GHSR1a and D1Rs) would provide necessary evidence to confirm 
dimerization.  
D2 Receptors 
The D2 receptor is found in several regions of the brain that also express the D1 
receptor; the ventral tegmental area, the nucleus accumbens, substantia nigra, the 
neostriatum, prefrontal cortex, hippocampus and the amygdala (Levey et al., 1993). 
Dimerization between GHSR1a and D2 receptors has been inferred from experiments 
that used the RET signal and co-immunoprecipitation as indicators (Wellman & Abizaid, 
2015). Strong fluorescence resonance energy transfer (FRET) signals from membrane 
preparations of hypothalamic and striatal tissue confirmed dimerization between 
GHSR1a and D2 receptors (Kern, Albarran-Zeckler, Walsh, & Smith, 2012). This 
dimerization leads to a switch in intracellular signaling pathways, causing a rapid 
increase in calcium release in the presence of a dopamine receptor agonist, an effect not 
observed in the absence of GHSR1a. However, unlike GHSR1a-D1R dimers, GHSR1a-
D2R dimers do not require endogenous ghrelin or a ghrelin receptor agonist to generate 
the effects of dimerization; the constitutive activity of GHSR1a is sufficient to modulate 
D2R signaling (Wellman & Abizaid, 2015). 
 
 
 
		
18 	
Implications for aversive fear learning 
Dopamine is potent modulator of aversive learning. Both, D1 and D2 receptors 
have been found in the amygdala, hippocampus, and prefrontal cortex; three major brain 
regions involved in processing fear memory (Ikegami, Uemura, Kishioka, Sakimura, & 
Mishina, 2014). The amygdala has been established as a critical brain region involved in 
encoding responses to discrete and contextual stimuli during fear conditioning paradigms, 
while the hippocampus is primarily involved in processing contextual fear memory 
(Ikegami et al., 2014; Phillips & LeDoux, 1992a; Selden, Everitt, Jarrard, & Robbins, 
1991).  
D1 receptor expression is particularly robust in the basolateral (BLA) and lateral 
(LA) divisions of the amygdala. A high density of D1Rs has been reported in the region 
that contains the intercalated cells, between the divisions of the amygdala (Muly et al., 
2009).  D1R stimulation in the basolateral amygdala (BLA) has been found to be 
imperative in the process of Hebbian learning, i.e., the formation of associations between 
conditioned and unconditioned stimuli in a fear conditioning paradigm (Guarraci, 
Frohardt, & Kapp, 1999; Lamont & Kokkinidis, 1998; Macedo, Martinez, Albrechet-
Souza, Molina, & Brandão, 2007; Nader & LeDoux, 1999). D2 receptors are primarily 
expressed in the central nucleus of the amygdala (CeA), and area demonstrating low to 
moderate concentration of the D1 receptor (Takahashi et al., 2010). Interestingly, a 
significant concentration of GHS-1a receptors has been found in the amygdala, 
specifically, in the BLA (Jensen et al., 2016) which contains the highest density of 
GHSR1a receptors within the amygdala (Alvarez-Crespo et al., 2012).  
		
19 	
The significant number of studies describing the expression of the GHS-1a and 
D1/D2 receptors within the amygdala provides a substantial argument for the co-
localization of these receptors at the level of single neurons in the amygdala. Thus far, 
there have been no studies that have demonstrated co-localization at level of single cells 
and possible heterodimerization between GHSR1a and D1R or D2R in the amygdala. It is 
necessary for future studies to employ techniques like FRET that can indicate the 
presence of dimers in membrane preparations of amygdalar tissue. If the presence of 
dimers within the BLA can be demonstrated, it would then be interesting to determine 
what components of the ghrelin system are active during fear conditioning paradigms, 
i.e., whether signaling is controlled primarily by GHSR1a-D1/2R dimers, or ligand-
dependent GHSR1a signaling, or solely because of the constitutive (ligand-independent) 
activity of GHSR1a. This would help delineate a mechanism by which the ghrelin system 
modulates the processing of fear memory.  
 
GHSR1a and the Serotonin system: GHSR1a-5HT2C heterodimers 
The serotonin system has been studied in the context of mood and anxiety 
disorders by a number of groups, implicating several subtypes of serotonin (5-HT) 
receptors as therapeutic targets for these disorders (Anderson & Mortimore, 1999; F G 
Graeff, Guimarães, De Andrade, & Deakin, 1996; Frederico G Graeff, 2004). Anxiety-
like behavior, specifically shock-induced fear and social avoidance can be simulated in 
rodents by activation of the 5-HT2C receptor in the BLA (Christianson et al., 2010; P. V 
Strong et al., 2011). Evidence of anxiogenic effects of 5-HT2C agonists in rodents and 
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humans (Stein, Ahokas, & de Bodinat, 2008; P. V. Strong et al., 2011), the negative 
effect of serotonin on ghrelin’s orexigenic effects (Wellman & Abizaid, 2015), and the 
inhibition of serotonin release by ghrelin in isolated hypothalamic synaptic terminals 
(Wellman & Abizaid, 2015) led to the investigation of the mechanism of interaction 
between the serotonin and ghrelin signaling systems (Jensen et al., 2016).  
5-HT2C receptors, like GHS-1a receptors, have been found in the choroid plexus, 
the hippocampus, substantia nigra, globus pallidus, hypothalamus, and the amygdala 
(Varnäs, 2005). Within the amygdala, these receptors are concentrated in the basolateral 
and central nuclei (Pockros-Burgess, Pentkowski, Der-Ghazarian, & Neisewander, 2014). 
Thus, the overlapping expression with GHSR1a receptors led to the hypothesis that 
GHSR1a and 5-HT2C receptors form dimers in the regions of co-expression. Indeed, 
Schellekens et al. reported the presence of a GHSR1a/5-HT2C heterodimer by transfecting 
HEK293 cells expressing GHSR1a-EGFP with lentiviral vectors to generate 5-HT2C 
expression within the cells. The dimerization leads to a 65% reduction in calcium 
accumulation in the presence of ghrelin or a ghrelin agonist, which can be recovered by 
administering a 5-HT2C antagonist to the system (Schellekens, Van Oeffelen, Dinan, & 
Cryan, 2012).  
Implications for fear learning 
Studies describing the expression profile of the GHSR1a and 5-HT2C receptors 
within the amygdala suggest co-localization of these receptors at the level of single 
neurons in the BLA. If heterodimerization between these receptors in the BLA were to be 
demonstrated, there could be a significant change in the interpretation of the mechanism 
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of ghrelin signaling in fear learning. For instance, if the shock-induced fear response 
were to be modulated by GHSR1a-5-HT2C dimers and not the constitutive activity of 
GHSR1a alone, therapeutic interventions would need to consider 5-HT2C as an additional 
target. The effects of attenuated ghrelin signaling as a result of dimerization could, in 
theory, be reversed by targeting an entirely different system.  
 
GHSR1a and the Melanocortin system: GHSR1a-MC3R heterodimers 
Co-expression of GHSR1a and Melanocortin-3 (MC3R) receptors in the neurons 
of the arcuate nucleus led to the investigation and subsequent demonstration of 
dimerization between the two receptors (Rediger et al., 2011). Expression of the 
Melanocortin-3 receptor (MC3R) has been reported in the hypothalamus and the 
mesocorticolimbic system, with a significant concentration in the arcuate nucleus (Olney, 
Navarro, & Thiele, 2014). The mesolimbic pathway is constituted by dopaminergic 
neurons that originate in the VTA, and terminate in the nucleus accumbens, ventral 
striatum, amygdala, bed nucleus of stria terminalis (BNST), lateral septum, and lateral 
hypothalamus (Adinoff, 2004). Although the precise expression profile of MC3Rs within 
the different divisions of the amygdala has not been explored yet, the expression of 
GHSR1a in several amygdaloid nuclei might allow for a preliminary hypothesis to be 
formed about the interaction of these receptors within the amygdala.  
Dimerization between GHSR1a and MC3R leads to a two-fold increase in cAMP 
accumulation associated with the MC3R protomer (Rediger et al., 2009). This a-
melanocortin stimulating hormone (a-MSH)-induced increase is dependent on the 
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constitutive activity of GHSR1a, and remains unaffected by the administration of ghrelin. 
Co-transfection of HEK293 cells with MC3R and a GHSR1a mutant that impairs or 
completely eliminates constitutive activity shows heterodimerization; however, the two-
fold increase in MC3R-associated signaling is not observed, indicating that the 
constitutive activity of GHSR1a is necessary to drive the effects of heterodimerization 
(Rediger et al., 2011). In addition to an MC3R-associated two-fold increase in signaling, 
dimerization results in a reduction of ligand-dependent as well as ligand-independent 
constitutive activity of GHSR1a by 40%, as measured by accumulation of intracellular 
calcium (Rediger et al., 2009).  
Implications for fear learning 
Although a detailed expression profile of MC3R within the nuclei of the 
amygdala remains to be developed, we can make inferences about the consequence of 
GHSR1a-MC3R dimerization in the amygdala. The dimerization adds a new layer of 
intricacy to the mechanism of ghrelin signaling in the processing of fear. If it is 
demonstrated that the BLA contains a significant concentration of MC3Rs, future studies 
would face the challenge of determining the constituents involved in processing shock-
elicited fear; i.e., GHSR1a-D1/2R, GHSR1a-5-HT2C, GHSR1a-MC3R heterodimers, or 
just GHSR1a constitutive activity; and to what extent each constituent participates in the 
process, in order to develop therapeutic targets that specifically target the pathway 
involved in the acquisition, consolidation, and extinction of fear memory. 
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GHSR1a and Cannabinoid-1 receptors: Potential heterodimers  
GHSR1a and cannabinoid-1 (CB1) receptor dimerization has not been 
demonstrated yet, although there has been speculation of the existence of heterodimers 
(Wellman & Abizaid, 2015). Ghrelin’s orexigenic effect and its hyper-stimulation of 
protein kinase activity in the hypothalamus is absent in mice treated with a CB1 
antagonist (Kola et al., 2008; Wellman & Abizaid, 2015). Electrophysiological 
recordings from parvocellular neurons in the paraventricular nucleus (PVN) have shown 
that administration of a CB1 receptor antagonist can reverse ghrelin’s inhibitory effect on 
excitatory terminals within the PVN (Kola et al., 2008; Wellman & Abizaid, 2015). Kola 
et al. also demonstrated how ghrelin-mediated endocannabinoid synthesis was lost in 
CB1 knock-out mice. Although this finding could indicate interaction of the two systems 
via dimerization, it could also imply that the cannabinoid system is a downstream target 
of ghrelin signaling (Wellman & Abizaid, 2015). 
Immunohistochemical studies have reported high density of CB1 receptors in the 
amygdala, hippocampus, and prefrontal cortex; neurons from each of these regions 
innervate the nucleus accumbens and VTA as part of the mesolimbic circuit (Katona et 
al., 2001). Within the amygdala, the highest concentration of CB1 receptors is found in 
the BLA, the nucleus of the lateral olfactory tract, and the intercalated nuclei between the 
divisions of the amygdaloid nuclei. Dense staining was also observed in the 
periamygdaloid cortex, the amygdalohippocampal area, and the anterior amygdaloid area 
(Katona et al., 2001). Thus, a high density of CB1 receptors in the BLA, which has 
already been characterized as a region where GHSR1a receptors are highly concentrated, 
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points in the direction of interaction between the two receptors. However, future studies 
would first need to demonstrate dimerization in membrane preparation of amygdaloid 
tissue, or in HEK293 cells co-transfected with plasmids expressing GHSR1a and CB1, 
before any hypothesis about the involvement of GHSR1a-CB1 heterodimers in the 
processing of fear can be made.  
 
Homodimers and Heterodimers within the GHSR family 
A recent study investigated the effects of homodimerization and 
heterodimerization on the conformation and resultant signaling cascades brought about 
by GHSR1a (Mary et al., 2013). The authors reconstituted a GHSR1a monomer, a 
GHSR1a-GHSR1a homodimer and a GHSR1a-GHSR1b heterodimer within a synthetic 
membrane system. GHSR1b is the product of alternative splicing of the ghsr gene 
encoding the GHSR1a protein; a non-signaling protein that was considered inactive until 
recently (Delporte & Christine, 2013). Mary et al. found that while homodimerization of 
GHSR1a does not have a significant effect on the constitution and signaling cascades 
employed by GHSR1a, heterodimerization with GHSR1b induced a conformational 
change in GHSR1a, resulting in a significant decrease in the constitutive activity of 
GHSR1a (Table 1). In order to determine whether GHSR1a constitutive activity is 
attenuated to the extent of causing an impairment in processing of fear, the magnitude of 
GHSR1a-GHSR1b binding in the amygdala, specifically within the BLA, must be 
investigated.  
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In conclusion, the extensive dimerization capacity of GHSR1a and the significant 
implications of its constitutive activity provide an insight into the degree of complexity of 
the ghrelin signaling mechanism (Table 1). In this study, we aim to bring to light an 
essential component of GHSR1a signaling that has not been explored before. Our review 
of the literature (Jensen et al., 2016; Yamamoto et al., 2009; Lutter et al., 2008), suggests 
that increased ghrelin receptor signaling generates a compensatory mechanism in the 
event of a stressful situation, i.e., elevated plasma levels of ghrelin indicate the presence 
of a counteractive response to stress. We hypothesize that increased ghrelin receptor 
signaling impairs the consolidation of fear memory, resulting in a decrease in fear 
behavior. Furthermore, our review of specific studies that address fear behavior (Meyer 
et al., 2014; Harmatz et al., 2016) led us to hypothesize that this impairment of fear 
memory processing results due to decreased consolidation and not acquisition of the fear 
memory. In order to test our hypothesis, we administered the ghrelin receptor GHSR1a 
exogenously into the BLA, keeping endogenous levels of ghrelin unchanged. We 
hypothesized that this manipulation would allow us to specifically study the effects of 
increased constitutive activity of GHSR1a on the processing of fear memory, providing 
an initial step in the direction of resolving the complex ghrelin signaling mechanism. 
Although an overexpression of the ghrelin receptor translates to an increase in binding 
sites for endogenous ghrelin, circulating levels of ghrelin in the central nervous system 
(CNS) are particularly low (Ferrini, Salio, Lossi, & Merighi, 2009), indicating that an 
impairment of fear memory consolidation, if observed, is in all likelihood due to 
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increased constitutive activity of GHSR1a and not due to an increase in binding sites for 
ghrelin.  
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METHODS 
All surgical procedures and behavioral paradigms were approved by the 
Institutional Animal Care and Use Committee of the Massachusetts Institute of 
Technology and performed in accordance with the US National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals. 
 
Subjects 
Adult male Long-Evans rats were used for all experiments (250-350g, Charles 
River, Raleigh, NC). Rats were housed individually in standard cages on hardwood chip 
bedding (68-72°F, 12-h light-dark cycle, 0700h lights ON) with a nylon chew toy. Food 
and water was provided ad libitum. We acknowledge that social isolation due to 
individual housing could potentially affect the stress response in rats (Turner, Sunohara-
Neilson, Ovari, Healy, & Leri, 2014); however, this was done to eliminate a potential 
confound due to the response to separation when performing behavioral analyses or 
handling the rats (Harmatz et al., 2016a). A recent study (Turner et al., 2014) studied the 
effects of single versus paired housing of adult male rats on plasma glucocorticoid levels 
and found no significant difference between the two groups. 
 
Virus  
Short-term (ST) HSV vectors were obtained from the Viral Vector Core at M.I.T. 
Replication-deficient HSV vectors were prepared in phosphate-buffered saline (PBS) + 
10% sucrose + 25mM HEPES (pH 7.3). The HSV p1005 plasmid is a modified HSV 
		
28 	
amplicon plasmid with a separate transcription cassette that expresses GFP. Expression of 
the target gene is driven by an IE4/5 promoter, while expression of GFP is driven by 
CMV (adapted from the HSV Manual; Viral Vector Core; M.I.T.). ST HSV-EGFP 
vectors were injected into “control/GFP” animals (Bilateral injection; 2µl per 
hemisphere), and ST HSV-GHSR1a-EGFP vectors expressing GHSR1a were injected 
into “experimental/GHSR1a” animals (Bilateral injection; 2µl per hemisphere). Titers for 
both control and experimental vectors were ~1x109 IU/ml. Expression of the virus in vivo 
peaks about 3-5 days post-injection. 
 
Stereotaxic Surgery 
Rats were allowed to acclimate to their surroundings in the animal facility for a 
minimum of three days before any surgical procedure was performed. Aseptic technique 
was followed for the entire length of the procedure. 
All surgical instruments were autoclaved the night before the surgery, and the 
syringes were washed thoroughly with sterile Milli-Q (MQ) water, PBS, and Maxicide. 
Surgical instruments were disinfected between surgeries, and surgical gloves were 
disposed of after completion of each surgical procedure. The surgical working area and 
stereotaxic apparatus was disinfected with 70% ethanol solution. Rats were weighed to 
determine appropriate concentration and volume of analgesics to be administered. 
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1. Equipment set-up and Anesthesia 
A Styrofoam platform covered with a sterile towel drape was used to mount the 
rats to the desired height within a dual-arm stereotaxic frame (Kopf Instruments, 
Tujunga, CA). Heat-pads were placed under the sterile drape to protect against 
hypothermia during long periods of surgery (Fornari et al., 2012). Before anesthetizing 
the rats, clean and dirty trays for surgical instruments were laid out on a sterile towel 
drape.  
An inhalant anesthetic, isoflurane, was used for the rats. Rats were placed in an 
induction chamber, after which the oxygen flowmeter was turned on and set to a flow rate 
of ~0.9-1L/min. Next, the isoflurane vaporizer was set to 4-5% for the induction phase of 
anesthesia. After about one minute, the vaporizer was adjusted to 2% for the maintenance 
phase of anesthesia, and the rat was transferred from the induction chamber to the 
stereotaxic apparatus. The breathing rate was monitored throughout the surgical 
procedure and the percentage of isoflurane was adjusted accordingly.  
 
2. Pre-surgical procedure 
Once the rat was transferred to the stereotaxic apparatus, the nose was placed in a 
nose-clamp fitted with an inhaler connected to the isoflurane vaporizer and the oxygen 
flowmeter. The rat’s reflexes were checked using the toe-pinch method of verification to 
ensure it was adequately anesthetized. Next, one of two ear bars used to stabilize the head 
into the stereotaxic frame was locked in at ~40mm. Supporting the head from beneath, 
the locked ear bar was guided into the external auditory meatus, followed by the other ear 
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bar. A pair of blunt forceps were used to open the mouth while pushing the incisor bar 
back so that the incisors fit just in front of the bar. After tightening the knobs on the ear 
bars and the nose-clamp, the position of the head was verified by moving the nose 
laterally from left to right while checking for an eye blink reflex. A small amount of 
Neomycin was applied to each of the eyes to provide lubrication and to protect against 
corneal damage during the surgery (Fornari et al., 2012). Ketofen was administered as an 
analgesic at a concentration of 5mg/kg/5ml via a sub-cutaneous route. Next, the head 
area, from the first vertebra up until the eyes, was shaved with an electric razor to prepare 
for the skin incision. Before performing the incision, the shaved area was sterilized for 
surgery using a mixture of iodine solution and 70% ethanol solution.  
 
3. Viral Infusion 
Using a pair of scissors, an anterior-posterior cut was made, extending about 2cm 
from the ears to the region between the eyes. This exposed the skull and the periosteum, 
which was scraped away with the pointed tip of iris/metzenbaum scissors. The skin was 
retracted with 4 pairs of clamps to widen the incision. Connective tissue and blood was 
removed using cotton swabs and tweezers to expose the skull. Next, a guide needle was 
placed over Bregma, and then over Lambda to record the dorso-ventral (DV) coordinate 
of these two points on the skull. To render the skull level, the nose bar was adjusted so 
that the DV coordinates of lambda and bregma were identical. The anterior-posterior 
(AP), dorso-ventral (DV), and medio-lateral (ML) coordinates of the BLA [-2.28mm, +/-
5.0mm, 7.0mm] were determined using a stereotaxic atlas of the rat brain (Paxinos and 
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Watson, Edition 7).  A 22-gauge metal needle with a beveled tip was attached to a 10µL 
Hamilton syringe connected to a micro-pump. The needle was moved over the Bregma to 
record its anterior-posterior and medio-lateral coordinates. After making the appropriate 
calculations to define the point of injection on each hemisphere, a hand drill was used to 
make burr holes at the two points. This was done very carefully to ensure that the drill bit 
did not penetrate the meninges or blood vessels. The holes were cleaned thoroughly with 
sterilized cotton-tipped applicators to ensure that all bone debris had been removed. The 
skull was also cleaned with MQ water and PBS solution. The dorso-ventral coordinates 
of the two target points on the skull were recorded by lowering the needle into the burr 
holes. A total of 4µL of the appropriate virus was drawn into the Hamilton syringe using 
the micro-pump. Pump-driven infusion of the virus was carried out at the rate of 
100nl/min, for a total volume of 2µL to be injected into the BLA in each hemisphere. 
After each injection, the needle was left in its position for 10 minutes to prevent backflow 
of the virus into the syringe. Once the injections were complete, the skin incision was 
closed using absorbable sutures. Suturing was performed perpendicular to the direction of 
the skin incision using an appropriate surgical needle and pair of forceps. 
 
4. Post-surgical treatment & care 
Once the rat was removed from the stereotaxic apparatus, iodine solution was 
applied to the wound area. The rat was then placed on a heat pad and monitored until it 
regained consciousness, after which it was returned to its cage.  
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All animals were monitored for a minimum of three days post-surgery to check 
for signs of distress and infection. Reduced spontaneous movement, distressed 
vocalization when handling, swelling in the area of the wound, and inadequate feeding or 
drinking due to reduced movement are signs of pain and distress (Geiger, Frank, Caldera-
Siu, & Pothos, 2008). If the animals showed any of these signs, we administered a sub-
cutaneous injection of Ketofen (5mg/kg/5ml).  
 
 
Behavioral Analyses: Pavlovian Fear Conditioning  
All animals received auditory Pavlovian fear conditioning and fear recall testing, 
as well as contextual fear recall testing. 
Animals were handled in a holding room for at least three days prior to the 
beginning of the fear conditioning paradigm. No behavioral testing was performed in this 
room. Rats were then transported to a behavioral testing suite that consisted of four 
sound-attenuating cabinets that contained a fear-conditioning chamber (10-inch-long X 8-
inch-wide X 7-inch-tall). Each of these cabinets was fitted with a fan, a tone-generator, 
and a light bulb (Baratta et al., 2016). Digital cameras were attached to the front wall of 
the cabinet, facing inward toward the fear conditioning chamber. The floor of the fear-
conditioning chamber was made up of steel rods (ENV-3013WR; Med Associates, St. 
Albans, VT), each of which was connected to a shock-generator (ENV-420S; Med 
Associates) in order to deliver the foot-shock stimulus to the rats. A programmable audio 
generator (ANL-926; Med Associates) delivered the tone stimulus. A multichannel pulse 
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generator (National Instruments, Austin, TX) synchronized the sequential presentation of 
stimuli by linking all outputs to a single source. 
All equipment was wiped with 70% ethanol solution before beginning a 
behavioral session, and also at the end of each session. 
Day 1: Fear Conditioning 
Rats were transported to the holding room where they had been previously 
handled an hour before being transferred to the behavioral testing suite. Before the 
beginning of the experiment, the tone intensity was calibrated (85db, 2200Hz) using a dB 
meter. The shock intensity (0.5mA) was calibrated using an oscilloscope with alligator 
clips (Chang et al., 2009) that were attached to the steel rods on the floor of the fear 
conditioning chamber. Med-test software (Med Associates, St. Albans, VT) was used to 
present the appropriate stimulus being calibrated. Infrared cameras (Med Associates, St. 
Albans, VT) recording behavior were calibrated using the VideoFreeze software to 
provide real-time video recordings (30 Hz) that could distinguish between a whisker 
twitch, tail flicks, and freezing behavior.  
The fear conditioning protocol was set up to provide 4 tone presentations 
(conditioned stimulus/CS; 85dB, 2200Hz, 30s) and 4 foot-shock presentations 
(unconditioned stimulus/US; 0.5mA, 2s) with a 28s inter-stimulus interval (ISI), a 120s 
inter-trial interval (ITI) and 120s initial habituation period before the presentation of the 
first conditioned stimulus. All animals received the same number of CS and US 
presentations. House lights, room lights, and a humidifier in the behavioral suite 
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remained ON for the length of the protocol. The fan fitted into the fear-conditioning 
cabinet also remained ON for the entire duration. 
The fear conditioning chambers were scented with 1% acetic acid before bringing 
the rats in for behavioral testing. Rats were transported from the holding room to the 
behavioral suite in black plastic boxes. All rats remained in the fear conditioning chamber 
for about 60s after the entire length of the protocol (600s) was run, after which they were 
transferred back into their home cage in the animal facility.  
 
Day 2: Contextual Fear Recall 
Contextual fear recall testing was performed for all rats, 24h after the beginning 
of fear conditioning. Rats were transferred to the holding room an hour before the 
contextual fear recall test was performed. The required equipment was calibrated as 
described before.  
Rats were exposed to the same context set up on Day 1; they were transferred to 
the behavioral suite from the holding room in black plastic boxes, and returned to the fear 
conditioning chambers that had been scented with 1% acetic acid. Rats remained in the 
chamber for 1200s, and were not exposed to any programmed stimuli (CS or US) for the 
entire length of the protocol. As on Day 1, house lights, room lights, the fan in the 
conditioning cabinet and the humidifier remained ON. About 60s after the end of the 
protocol, rats were transferred back into their home cage in the animal facility. Infrared 
cameras and VideoFreeze software was used to record behavior during the session. 
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Day 3: Auditory Fear Recall 
To test for auditory fear recall, rats were exposed to a novel context 24h after the 
beginning of the contextual fear recall test. To set up this novel context, the grid floor, 
and back and side walls of the fear conditioning chamber were covered with white 
Plexiglas inserts, the chamber was scented with 0.3% Pine-Sol, and the humidifier, the 
fan in the fear conditioning cabinet, the house lights and the room lights were all turned 
OFF. Instead of the house and room lights, a 25W red light bulb was used to provide 
illumination. Rats were transferred from the holding room to the behavioral suite in clear 
plastic boxes. All required equipment was calibrated as described before. 
The fear recall protocol (1500s) was set up to provide 10 tone presentations 
(conditioned stimulus/CS; 85dB, 2200Hz, 30s) with an inter-trial interval of 120s and a 
habituation period of 120s before the first tone was presented. All animals received the 
same number of auditory stimulus presentations. Rats were transferred back to their home 
cage 60s after the end of the protocol. 
A freezing response to the auditory stimulus was defined as “the absence of all 
movement except that which required respiration” (Baratta et al., 2016). Infrared cameras 
and VideoFreeze software captured movement and freezing behavior at a frequency of 30 
frames/second. Locomotion was determined using the motion index, a value returned by 
VideoFreeze that corresponds to the average change in the greyscale pixel values in the 
recorded video. A higher motion index was indicative of greater locomotive activity 
(Harmatz et al., 2016b). Freezing was measured by first counting the number of 
observations below a pre-determined threshold value of motion index and then dividing 
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this number by the total number of observations recorded during a session to express the 
freezing response as a percentage (Harmatz et al., 2016b). the threshold was defined as 
“the value of the motion index below which only movement that required respiration was 
recorded” (Harmatz et al., 2016b). 
 
Intracardial perfusion  
All rats were perfused the day after behavioral testing was performed. 4% 
Paraformaldehyde (PFA) solution for perfusion was prepared fresh; on the day of, or the 
night before the perfusion. 
Preparation of PFA (4%, for one animal) 
4% PFA solution was prepared under a fume hood. All apparatus used in the 
preparation was specifically assigned for storing PFA. About 150ml of MQ water was 
heated to 65°C on a hot plate, while stirring. The temperature was monitored with a 
thermometer to ensure that the solution remained at 65°C throughout the process. 8g of 
PFA was measured out in the fume hood, and slowly added to the heated MQ water on 
the agitator. About 2 drops of 1N Sodium hydroxide solution was added to the mixture to 
facilitate dissolution of the PFA. Once the PFA was dissolved, 20ml of 10X phosphate 
buffered saline (PBS) was added to the reaction. The mixture was topped up with 30ml of 
MQ water for a total of 200ml of 4% PFA. The pH of the solution was adjusted to around 
7.3 units using 2-3 drops of Hydrochloric acid (HCl). The solution was filtered and stored 
at 4°C overnight. 
 
		
37 	
Perfusion  
An empty cage was filled halfway with water. 1X PBS solution and 4% PFA 
solution was drawn into reusable syringes (~60ml/syringe). Once the rat was 
anesthetized, it was taped onto the steel grids attached to the cage. A lateral incision (4-
5cm) was made in the abdominal wall to expose the liver and the diaphragm, using 
forceps and a pair of scissors. The diaphragm was cut along the entire length using blunt 
scissors to expose the thoracic cavity. Next, the rib cage was cut on both sides up to the 
collarbone so that the sternum could be lifted. The xiphoid process was clamped and 
pulled over the head using a hemostat to gain better access and get a clear view to the 
heart and the great vessels. A 15-gauge perfusion needle was inserted into the left 
ventricle and passed through the ascending aorta. A hemostat was used to clamp the 
needle and secure its position. Next, a small incision was made in the right atrium using 
iris scissors to create a pressure-release outlet. About 120ml of 1X PBS solution was 
infused into the system, using constant pressure to ensure steady infusion. Next, the 
systemic saline was replaced by infusing about 180ml of 4% PFA through the system. 
The rat was stiff at the end of the perfusion. 
Brain Dissection 
The head was removed using a guillotine. A midline incision extending from the 
neck to the eyes was made using a razor blade to expose the skull. Muscles at the base of 
the skull were incised to gain access to the foramen magnum. A cut was made from the 
inside of the foramen magnum extending to the distal side of the skull. This was done on 
both sides, after which rongeurs were used to peel the skull around the cerebellum away. 
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Next, a pair of scissors was used to lift the dorsal surface of the skull, in order to facilitate 
the process of peeling it away with rongeurs. The olfactory bulb, optic nerves, and other 
nervous connections on the ventral surface were severed with a spatula in order to 
remove the brain from the head. The brain was placed into a vial containing 4% PFA 
solution for 24-48h at 4°C.  
 
Post-fixation processing of the brain  
Post-fixation, the brains were transferred to vials containing 30% sucrose solution 
and placed on a shaker in a cold room. After about 3 days, the brains were removed from 
the vials and stored at -80°C until they were ready for sectioning. Brains were sectioned 
(frontal sections) at 40 microns using a cryostat (Leica Biosystems, Danvers, MA). 
Sections were mounted onto gelatinized slides and Vectashield mounting medium with 
DAPI (Vector Labs, Burlingame, CA) was applied to the slides to prepare for 
fluorescence imaging.  
GFP-expressing neurons were examined under an inverted fluorescence 
microscope (Nikon E800 Fluorescence microscope, 10X) to determine the accuracy of 
our coordinates for the BLA and the site of injection.  
 
Statistics 
All statistical comparisons were made using StatView for Windows (Version 
5.0.1; SAS Institute, Cary, NC). Repeated measures ANOVAs were used to analyze all 
data, followed by post hoc analysis (Fisher’s least significant difference; FLSD). For all 
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comparisons, the statistical significance (a) was set at 0.05, i.e., data was considered 
significant if the P-value was <0.05. Statistical trends in data were noted when p>0.05 but 
<0.10, and any data corresponding to a p-value>0.10 was considered insignificant. All 
data was presented in ANOVA tables as ± standard error of the mean (S.E.M.) 
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RESULTS 
We used an animal model of associative fear learning in which rats were injected 
with a control HSV.eGFP plasmid, or an HSV amplicon plasmid constructed to express 
GHSR1a and GFP in the BLA.  
 
Increased ghrelin receptor signaling does not affect the acquisition of fear 
All rats (n=14) underwent auditory fear conditioning 3-5 days after exogenous 
administration of the GHSR1a plasmid (experimental group) or the GFP plasmid (control 
group). The session consisted of a two-minute habituation period followed by four 
presentations of the conditioned stimulus reinforced by an aversive foot-shock stimulus 
(Figure 1A, B). We analyzed data from this session to investigate the effect of increased 
ghrelin receptor signaling on fear acquisition. Although a slight impairment of fear 
acquisition was seen in the experimental group, this did not reach statistical significance 
(Figure 1C, D; F=1.648, p=0.31). This served as preliminary evidence in support of our 
hypothesis, which states that ghrelin signaling in the BLA negatively impacts the 
consolidation and/or retrieval of fear memory, but not the acquisition of fear memory.  
As expected, the first two minutes of the conditioning, in which the animals 
habituated to and explored their surroundings, were characterized by near-negligible 
levels of freezing for both groups (GFP group: 1.65%; GHSR1a group: 4.20%). Animals 
in both groups demonstrated increased levels of freezing as they were exposed to 
additional CS-US pairings; however, for the control group, this increase was significant 
for the period between the second minute of habituation, “M2 D1”, and the first CS-US 
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pairing, “T1 D1” (p=0.03), and the period between the first CS-US pairing and the 
second CS-US pairing, “T2 D1” (p=0.05). After the second CS-US pairing, freezing 
levels continued to increase, but were not significantly different from the level of freezing 
at “T2 D1”. For the experimental group, the increase in freezing was significant for the 
period between the first CS-US pairing, “T1 D1” and the second CS-US pairing, “T2 D1” 
(p=0.01). As was seen in the control group, freezing levels continued to increase after the 
second CS-US pairing, but were not significantly different from the level of freezing at 
“T2 D1”. This indicates that the animals were able to associate the conditioned stimulus 
(tone) with the unconditioned stimulus (foot-shock) as early as the second trial in the fear 
conditioning paradigm, in accordance with previous studies that have described how 
conditioned freezing occurs at the “highest rate early in training”(Lindquist, Mahoney, & 
Steinmetz, 2010). 
 
Enhanced ghrelin receptor signaling impairs contextual fear recall  
All rats underwent contextual fear recall testing exactly 24h after the 
administration of auditory fear conditioning. Rats were exposed to the same context as on 
the day of training (Day 1) without the presentation of conditioned or aversive stimuli in 
order to extinguish their association of the context with fear (Figure 2A, B). Even though 
we planned to use a novel context (different from the day of training) for auditory fear 
recall testing, we wanted to ensure that the freezing response associated with all aspects 
of the context on Day 1 was extinguished and that any freezing response observed during 
auditory testing was only in response to the tone, not the context. For instance, while 
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humans might not be sensitive to trace odor from the scented conditioning chamber on 
the first day of the paradigm, a rodent’s superior sense of smell (Bijland, Bomers, & 
Smulders, 2013) could lead to a potential confound in the quantification of freezing 
behavior on Day 3. Other than scent, the ceiling and front wall of the chamber remained 
uncovered by Plexiglas inserts, essentially retaining their appearance from Day1 of the 
paradigm. Therefore, contextual extinction on Day 2 served as a means of extinguishing 
generalized fear to the context. The process of reduction in the fear response, referred to 
as “extinction”, has been hypothesized to bring about processing of a new memory, one 
that competes with the contextual fear memory; and does not associate the complex, 
polymodal stimulus (context) with an aversive stimulus (Jovanovic, Nylocks, & 
Gamwell, 2013; Quirk, 2002).  
For the “control” rats, we expected to see a higher freezing percentage during the 
first few minutes spent in the chamber, followed by a gradual decrease in freezing 
indicating successful extinction. For the “experimental” rats, we expected the increased 
ghrelin signaling to interfere with, and impair fear memory consolidation and retrieval, 
which is why we did not expect to see a similar extinction curve as in the case of control 
rats, but an overall decrease in freezing percentage right from the beginning of the 
protocol. Although our hypothesis primarily addresses the relationship between auditory 
fear memory and increased ghrelin signaling in the BLA, we acknowledge the 
involvement of the BLA in processing fear responses to auditory, visual and contextual 
stimuli (Gale, 2004). Several lesion studies (Kim & Davis, 1993; Phillips & LeDoux, 
1992b) have reported that while the amygdala is involved in coordinating a fear response 
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to modality-specific (tone) as well as “complex polymodal” stimuli (context), the 
hippocampus encodes only contextual fear memory and does not process a fear response, 
if any, to the cue (tone). 
As expected with the rats in the control group, we did see a high percentage of 
freezing for the first two minutes of the session (Figure 2C; average percent freezing for 
first 120s—50.8%), and this percentage was reduced to 22.3% as early as Minute 6 
(paired t-test, p=0.09) validating our contextual extinction paradigm. Although the 
difference in freezing percentages did not reach statistical significance, the data was 
trending towards significance (0.05<p<0.10), and a higher “n” (n>14) would help 
establish a stronger validation of our methods. 
In the case of the experimental group, we did see an overall decrease in freezing 
percentage as compared to the control group (Figure 2C; F=3.345, p=0.092). Although a 
higher “n” would allow for more robust evidence in support of our hypothesis, the data 
trending toward significance is an indicator of the role of ghrelin signaling in the BLA in 
impairing consolidation and/or retrieval of fear memory to the context. In both groups, 
we observed an increase in freezing levels during the last three to four minutes of the 
session. This increase does not reflect “freezing”, but is rather an effect of decreased 
exploration in rats towards the end of a behavioral session (also seen on the third day of 
behavioral testing, i.e., auditory fear recall testing; Figure 3C, D, E). When we watched 
video recordings of the contextual extinction sessions, we saw that this decreased activity 
toward the end of the session did not resemble freezing behavior observed, say, at the 
beginning of the same session or the freezing response to tone-shock pairings on Day1.  
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Increased ghrelin signaling impairs the consolidation and/or retrieval of auditory fear 
memory 
On the third day of behavioral testing, all rats were exposed to a novel context 
wherein the conditioned stimulus was repeatedly presented without reinforcement by the 
aversive (foot-shock) stimulus. In theory, this should reduce the fear response elicited by 
the sounding of the tone as we progress from the beginning of the session to the end. This 
assumption is in accordance with the hypothesis about the process of extinction, 
described earlier. We expected to see an extinction curve for both, control and 
experimental groups; more importantly, we expected to see a decrease in the recall of 
auditory fear memory in the “experimental” group as per our hypothesis.  
As expected, we observed a significant decrease in auditory fear memory recall in 
the experimental group as compared to the control group (Figure 3E; F=5.803, p=0.033). 
We also examined the data after eliminating “post-tone” periods (120s inter-trial periods) 
so that we could make inferences based solely on the difference in freezing response to 
the tone period (30s). We observed a decrease in auditory fear memory in the 
experimental group that reached a level of significance even greater than when we 
compared the two groups across the entire length of the session (Figure 3C; F=6.501, 
p=0.025). We would like to point out that the habituation period (first 120s of session) 
should, in theory, not show a marked difference in freezing percentage between the 
groups; all rats are expected to explore the novel context during this period, 
demonstrating negligible freezing. Indeed, we recorded very low levels of freezing in 
both groups during this period (3% for experimental group; 16% for control group). The 
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difference in freezing percentage between two groups for the habituation period did not 
reach significance (p=0.23 for Minute 1 of habituation; p=0.10 for Minute 2 of 
habituation). These observations led to the construction of a dataset that allowed us to 
view the freezing response specifically to the ten tone presentations (post-tone period and 
habituation period excluded). Evidently, we recorded a decrease in freezing levels in the 
experimental group, at the highest level of significance thus far (Figure 3D; F=6.866, 
p=0.022). In addition, both groups showed a significant increase in freezing during the 
period between the second minute of habituation and the first tone presentation (Figure 
3C; for experimental group, p=0.006; for control group, p=0.06). 
An important observation was the absence of a distinct extinction curve for the 
control group—freezing levels dropped slightly after the first two presentations of the 
conditioned stimulus, however, this decrease was not significant (p=0.33). However, this 
was not due to control rats showing unusually high freezing levels across the session. We 
realized that the freezing percentage recorded for the first two tone presentations 
averaged to approximately 63% (Figure 3C, D) because of the unusual behavior of two 
control rats that showed negligible levels of freezing specifically to the first two tone 
presentations. We did not eliminate these rats from our analysis because they were able to 
acquire auditory fear memory on Day 1 of our paradigm (freezing levels recorded on Day 
1 were expected/normal). As a result, the freezing percentage to the first two tone 
presentations, although eventually recorded as ~63%, could have been significantly 
higher, returning a more distinct extinction curve. A higher “n” would allow for a more 
thorough analysis of the effect of increased ghrelin receptor signaling on the 
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consolidation and/or retrieval of fear memory. As was seen during contextual fear recall 
(Figure 2C), a slight increase in freezing toward the end of the session (Figure 3C, D, E; 
trials 8, 9 and 10) seemed unusual at first, but when we looked at a video recording of the 
session, we realized that this freezing behavior was only a result of decreased activity in 
the animals toward the end of a behavioral session, and did not resemble the freezing 
response to the first few tones of the session. 
 
Post-behavioral analysis of GFP expression  
HSV vectors expressing GFP and GHSR1a (experimental group) or GFP alone 
(control group) were infused into the BLA. 24h after the behavioral analysis was 
complete, we perfused all the rats and dissected the brain for fixation and post-fixation 
processing. A Nikon E800 fluorescence microscope was used to assess for GFP 
expression at site of injection. Representative images (10X magnification) of GFP 
expression have been demonstrated (Figure 4 Left and Right; left and right hemispheres 
of the brain). 
 
(The remainder of the Results section, consisting of tables, figures and figure legends, 
has been provided in the Appendix) 
 
 
 
 
		
47 	
DISCUSSION 
We developed a model to investigate the modulatory effect of the constitutive 
activity of the ghrelin receptor GHSR1a on fear memory acquisition and consolidation. 
This was achieved by virus-mediated overexpression of GHSR1a in the BLA without 
concurrent manipulation of endogenous levels of ghrelin. Jensen et al. used a similar 
methodology of AAV-mediated overexpression of the ghrelin receptor; however, for that 
study, virus was infused into the amygdalar region to investigate the effect on anxiety and 
depression-like behavior, not fear behavior.  
Our analysis suggests that increased ghrelin receptor signaling significantly 
impairs the consolidation of auditory fear memory (Figure 3C, D, E). In addition, we 
found that enhanced ghrelin signaling did not seem to modulate the process of acquisition 
of fear, as seen from quantification of freezing response on first day of our behavioral 
paradigm (Figure 1C, D). Finally, in terms of contextual fear memory, although we did 
not achieve a similar level of significance when analyzing the difference in freezing 
response of the control (GFP) and experimental (GHSR1a) groups, we observed an 
impairment in consolidation of fear memory in GHSR1a rats (Figure 2C), with our data 
trending toward significance.  
The effect of increased GHSR1a signaling on fear memory consolidation could 
not be dissociated from its effect on fear memory retrieval. This is because we injected all 
animals 3-5 days prior to behavioral testing. Therefore, even though we observed a 
marked decrease in the fear response on the day of auditory fear recall (Day 3 of the 
paradigm), we have no evidence of whether this occurred as a result of impaired retrieval 
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or impaired consolidation of fear memory. Although we did not perform a follow-up 
experiment, we devised a method to investigate whether increased ghrelin signaling 
impairs the consolidation or retrieval of fear memory. Instead of exogenously 
administering GHSR1a prior to behavioral training, we propose that infusion of the virus 
into the BLA 24h after auditory fear conditioning (Day 1 of behavioral analysis) would 
allow us to observe the effects of enhanced ghrelin signaling, specifically on the retrieval 
of fear memory. This was designed keeping in mind that the first 24 hour-period after a 
memory (fear) is acquired is critical for its consolidation (Essentials of Psychology: 
Concepts and Applications - Jeffrey S. Nevid - Google Books, 2014), therefore, we are not 
interfering with the process of consolidation. A significant difference in freezing levels of 
control and experimental groups in this revised paradigm would indicate that ghrelin 
signaling was involved in the retrieval of fear memory, and not its consolidation. Future 
studies would of course be required to provide evidence to support these claims. 
Although our results suggest that ghrelin signaling does not modulate the 
acquisition of fear, one study reported that ghrelin modulates neural activity in the lateral 
amygdala (a division of the basolateral complex of the amygdala), subsequently leading 
to an impairment in the acquisition, but not consolidation of conditioned taste aversion 
(CTA) (Song et al., 2013). However, to investigate the effect of enhanced ghrelin 
signaling on consolidation of CTA memory, ghrelin infusions were given 20 minutes’ 
post aversion training instead of immediately after training—at this point, the process of 
consolidation of the aversive memory has already begun. An important consideration is 
the means by which ghrelin signaling is amplified. In the study by Song et al., ghrelin 
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signaling was increased by ligand-dependent activity of GHSR1a, while our study is 
focused on increased ghrelin signaling due to increased constitutive (ligand-independent) 
activity of GHSR1a. If we refer to the summary table of GHSR1a dimerization (Table 1), 
we can see how both of these manipulations amplify the ghrelin signaling cascade, but 
through different routes, i.e., dimerization with different neuromodulatory receptors 
within the BLA. Although we do not know whether the effect on fear memory 
consolidation and/or retrieval seen in our study is solely a result of the constitutive 
activity of GHSR1a or whether it is the result of GHSR1a forming a heterodimer with 
any one of the five neuromodulatory receptors it is known to dimerize with; assuming the 
latter, we can see (from Table 1) how, depending on the heterodimer, ligand-dependent or 
ligand-independent constitutive activity of GHSR1a functions to activate or attenuate 
different signaling mechanisms. Therefore, Song’s methods might induce amplification 
of D1R or 5-HT2C signaling via the GHSR1a-D1R dimer or the GHSR1a-5HT2C dimer, 
both activated by the ligand ghrelin, which could ultimately block acquisition of CTA 
memory. Our study on the other hand, might result in amplification of D2R or MC3R 
signaling via the GHSR1a-D2R or GHSR1a-MC3R dimer, both activated solely by the 
constitutive activity of GHSR1a and not the ghrelin ligand.  
We report an attenuation of fear behavior in rats following GHSR1a 
overexpression. We based our hypothesis of involvement of the ghrelin system in 
modulating a fear response partly on the finding that adrenergic receptors present a high 
concentration of ghrelin-producing cells and that adrenaline is a potent stimulator of 
ghrelin release in response to stress, implicating a counter-active role of ghrelin in 
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modulating behavior in stressful situations (Jensen et al., 2016). However, some studies 
have reported an increase in anxiety-like or depression-like behavior (a form of aversive 
behavior) as a result of ghrelin administration (Currie et al., 2012b; Hansson et al., 2011). 
However, it is essential to note that Hansson et al. studied the effect of chronic infusion 
of ghrelin over a 2-week period. Our study developed a model of acute ghrelin infusion 
in the rodents—a study (Meyer et al., 2014) reported how this difference in duration of 
infusion brings about very distinct effects on fear memory. The authors reported an 
enhancement of fear memory as a result of repeated stimulation of the ghrelin receptor by 
infusion of a ghrelin agonist on 5 consecutive days in naïve rats. They also reported how 
a single infusion of a GHSR1a agonist or a single “immobilization” (stress) session 
impaired fear processing in rats. Furthermore, a more recent study (Harmatz et al., 
2016a) has even delineated a mechanism by which repeated ghrelin receptor stimulation 
causes the enhancement of fear memory. Harmatz et al. described how the enhancement 
of fear memory is actually a result of central ghrelin resistance, i.e., a decrease in binding 
sites for ghrelin or ghrelin agonists as a consequence of chronic stress. Thus, this suggests 
that the enhancement of fear memory does not occur due to enhanced ghrelin signaling, 
but due to a dysfunctional ghrelin system following a deficiency of appropriate binding 
sites for ghrelin caused by chronic stress. 
The study by Currie et al., as well as other studies (Sah, Faber, Lopez De 
Armentia, & Power, 2003) which have reported an increase in anxiety/depression-like 
behavior in rats following an exogenous administration ghrelin have also reported 
modulation of cannabinoid and dopaminergic activity in the amygdala. This is another 
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reference in support of our suggestions about the complexities of the ghrelin signaling 
pathway and the challenges associated with delineating a specific mechanism that brings 
about fear processing because of the extensive capacity of GHSR1a to dimerize with a 
host of neuromodulatory receptors like CB1 (Cannabinoid 1) and D1R or D2R 
(Dopamine 1 & 2 receptors). This dimerization, as explained before, could lead to 
changes in signaling pathways depending on whether activity in the GHSR1a protomer is 
ligand-dependent or ligand-independent. Another effect of dimerization might be that if 
the ratio of GHSR1a involved in heterodimers to independent GHSR1a receptors is too 
high, ghrelin signaling via independent GHSR1a receptors is reduced, and it could be that 
this dysfunction in the ghrelin system results in the anxiolytic effects observed.  
However, in order to validate this claim, future studies would need to focus on 
determining a mechanism by which we are able to assess what percentage of fear, anxiety 
or depression-like behavior is driven by GHSR1a heterodimers as opposed to 
independent GHSR1a receptors. 
The density of the GHSR1a receptor in the hypothalamus, hippocampus and 
amygdala alludes to a role for ghrelin signaling in stress-related disorders of fear, anxiety 
and depression. The particularly high concentration of this receptor in the basolateral 
complex of the amygdala, an area associated with processing negative emotional states 
like fear (Lutter et al., 2008a; Meyer et al., 2014) led to our investigation of the role of 
GHSR1a, specifically the constitutive activity of GHSR1a in the processing of fear 
memory. Our study is thus the first to investigate the effect of acute infusions of GHSR1a 
into the BLA on fear memory. Although we acknowledge that a constant level of ghrelin 
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secreted into a system might indicate that the observed impairment of fear memory 
consolidation is not just a result of increased constitutive activity of GHSR1a, but also a 
result of increased binding sites for circulating ghrelin, we also note that these levels of 
circulating ghrelin are particularly low in the central nervous system (CNS). Local 
synthesis of ghrelin in the CNS has not been established in any of the areas where effects 
of ghrelin signaling have been reported, making peripheral circulating levels of ghrelin 
the sole endogenous source for binding sites in the hippocampus, hypothalamus, 
amygdala and midbrain (Ferrini et al., 2009). The existence of a central source of ghrelin 
(in neurons or glia) remains debatable and a direction for future studies. 
In conclusion, we report an impairment of fear memory consolidation and 
expression due to increased GHSR1a constitutive activity in the BLA. Our work serves to 
put together one of the pieces in the complex ghrelin signaling mechanism, and although 
several other components of this mechanism, including heterodimers and homodimers of 
GHSR1a, have yet to be explored in the context of processing of fear memory, this study 
provides a step in the direction of establishing ghrelin as a novel biomarker for stress-
induced mental disorders.  
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